AFFY Affymax Inc.
- 1.0378 P/E
- 75.9637 P/S
- 0.6167 P/B
- 0.0820 EPS
- 0.05 / N/A % Dividend
- 38,236.00 Avg. Vol.
- 37.49M Shares
- 3.19M Market Cap.
Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...
MicroCap Daily - Nov 3, 2014
Business Wire (press release) - Nov 26, 2014
HotStocked - Jun 17, 2014
Insider Monkey (blog) - Jun 10, 2013
GlobeNewswire (press release) - Mar 4, 2013
GlobeNewswire (press release) - Jul 18, 2013
iStockAnalyst (press release) - Feb 25, 2013
Down 85%! Why Affymax Is Getting Crushed This Morning - Motley Fool
Seeking Alpha - Jun 4, 2013
Insider Monkey (blog) - Apr 8, 2013
Seeking Alpha - Feb 6, 2013